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Purpose: Age-related macular degeneration (AMD) is the major cause of blindness among persons aged 60 years and
older. The current approved therapies for AMD are exclusively limited to inhibiting vascular endothelial growth factor.
However, substantial improvement in vision occurs in only one-third of patients treated with vascular endothelial growth
factor antagonists, and one-sixth of treated patients still progress to legal blindness. Therefore, more specific targets are
needed to treat AMD. Our goal was to find secretory proteins that change in number in the aqueous humor and that cause
exudative AMD disease.
Methods: The number of molecules changed in the aqueous humor of patients with AMD compared to the control group
was determined using antibody array analysis. The levels of angiopoietin-2 and insulin-like growth factor binding protein-
related protein 7 were measured using enzyme-linked immunosorbent assay. The levels of T-cell cytokine receptor (TCCR/
WSX-1) were determined using western blot. Potential TCCR/WSX-1-mediated effects on tube formation as well as
phosphorylation of extracellular signal-regulated kinase in human umbilical vein endothelial cells were determined.
Results: We found that the numbers of several molecules were changed in the aqueous humor of patients with AMD
compared to the control group. Among them, angiopoietin-2 was reduced by 20% and TCCR/WSX-1 was increased
twofold. Moreover, exogenous TCCR protein induced tube formation and phosphorylation of extracellular signal-
regulated kinase in human umbilical vein endothelial cells.
Conclusions: Our study suggests that TCCR/WSX-1 is closely associated with angiogenesis and could serve as a novel
therapeutic target in patients with AMD.
Exudative age-related macular degeneration (AMD) with
characteristic  choroidal  neovascularization  (CNV)  causes
irreversible  loss  in  visual  acuity  in  elderly  patients  [1,2].
Treatments currently available for the disease include laser
photocoagulation,  verteporfin  photodynamic  therapy,  and
intravitreal injections of corticosteroids and antiangiogenic
agents [3,4]. Many studies have reported the benefits of each
treatment, although none is without risks. Because AMD is
complex, the cause of the disease is largely unknown.
Currently, numerous studies have demonstrated that the
concentrations of various secretory molecules are increased
and caused the disease in patients with AMD: Interleukin
(IL)-6, IL-8, IL-10, C-reactive protein, monocyte chemotactic
protein (MCP)-1, and vascular endothelial growth factor A
(VEGF-A)  [5-8].  Among  these  molecules,  proangiogenic
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factor VEGF-A has been validated in patients with AMD with
CNV, and VEGF-A-neutralizing agents such as bevacizumab
(Avastin),  ranibizumab  (Lucentis),  and  pegaptanib
(Macugen) have recently been studied for treating the disease
[9,10]. However, problems remain with its curative value and
safety concerns, and targets for CNV that are more specific
are needed.
Thus, the purpose of the present study is to investigate
changes in the concentration of various secretory molecules
in the aqueous humor of patients with AMD and to determine
whether these molecules could induce angiogenesis.
METHODS
Preparation  of  patient  samples:  This  clinical  study
investigated  the  levels  of  various  proteins  in  the  aqueous
humor of patients with CNV secondary to AMD and in normal
control cataract patients. This study was approved by the
Institutional Review Board of Kim’s Eye Hospital, Seoul,
Korea. Informed consent was obtained from all participants.
Patients were enrolled from the Retina Center at Kim’s Eye
Hospital from March 2010 to August 2010. Patients (male:
Molecular Vision 2012; 18:234-240 <http://www.molvis.org/molvis/v18/a27>
Received 28 November 2011 | Accepted 25 January 2012 | Published 28 January 2012
© 2012 Molecular Vision
23422, female: 13) over 50 years old with active CNV secondary
to  AMD  identified  with  fluorescein  angiogram  who
underwent  injections  of  0.5  mg  of  ranibizumab  with
paracentesis  of  the  aqueous  humor  before  injection  were
included in this study. Exclusion criteria were as follows: (1)
ocular disease apart from AMD and cataract; (2) previous
ocular  surgery  apart  from  cataract  surgery,  photodynamic
therapy  with  verteporfin,  and  intravitreal  triamcinolone
injection; and (3) cataract surgery, intravitreal triamcinolone
injection, and photodynamic therapy within 6 months before
entry in the study. Undiluted aqueous humor samples (100–
150 μl) were obtained through anterior chamber paracentesis
from 30 eyes in 35 patients with AMD. All patients did not
have significant systemic diseases. Undiluted aqueous humor
(100–150 μl) was also obtained as a control sample from 24
eyes  immediately  before  cataract  surgery.  Samples  were
stored  at  −80  °C  until  analysis.  No  significant  statistical
difference  was  noted  in  the  mean  age  of  the  age-related
macular  degeneration  group  (67.9±8.7  years)  versus  the
control group (64.4±10.7 years).
Membrane-based human antibody array: In this study, we
examined the differences in protein expression levels between
the aqueous humor of controls and patients with AMD by
profiling  the  proteins  using  RayBio®  Biotin  Label-based
Human Antibody Array I (Catalog No: AAA-BLM-1–2; Ray
Biotech, Inc., Norcross, GA). The array membrane is spotted
with 507 specific antibodies toward cytokines, chemokines,
adipokines,  growth  factors,  angiogenic  factors,  proteases,
soluble  receptors,  soluble  adhesion  molecules,  and  other
proteins  in  culture  supernatant  and  serum.  Biotinylated
proteins  of  samples  can  be  captured  by  these  specific
antibodies  and  horseradish  peroxidase  (HRP)-conjugated
streptavidin  in  a  sandwich  format.  After  enhanced
chemiluminescence (ECL) solution was added, the signals can
be  visualized  with  chemiluminescence.  The  assay  for
antibody  arrays  was  performed  according  to  the
manufacturer’s  instructions.  Briefly,  to  biotinylate  the
samples,  50  μl  of  each  undiluted  aqueous  humor  sample
(control or patients with AMD, 24 cases each) was mixed and
dialyzed with phosphate buffer saline (PBS; 137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4), and
an internal control was added to the dialyzed samples. After
1.5 μl of labeling reagent was added to the samples and they
were incubated at room temperature (RT) for 30 min, the
reaction was stopped with 5 μl of stop solution. Free biotin
was removed with the spin column, and the biotin-labeled
samples were diluted with 7 ml of blocking buffer. Array
membranes were blocked with 8 ml of 1× blocking buffer at
RT for 1 h, and then incubated with the biotin-labeled samples
at 4 °C overnight. Then the membranes were washed three
times  with  20  ml  of  wash  buffer  I  and  II,  followed  by
incubation with 8 ml of 500-fold diluted HRP-conjugated
streptavidin for 2 h at RT. After the membranes were washed,
mixed detection buffer was loaded onto the membranes to
cover the entire surface, and they were incubated for 2 min.
Finally,  spot  signals  were  visualized  by  exposing  the
membranes to radiographic film (Kodak X-OmatTM; Kodak,
Rochester,  NY)  for  variable  times.  To  select  the  target
molecules  showing  significantly  different  spot  signal
intensities between controls and patients with AMD, results
from multiple films were compared by three persons in a
blinded manner. Biotinylated and non-biotinylated proteins
placed on the membranes were used as positive and negative
controls, and internal controls were used to monitor the whole
process including biotin-labeling.
Protein  quantitation:  The  levels  of  angiopoietin-2  and
insulin-like growth factor binding protein 7 (IGFBP-7) were
measured  using  sandwich  enzyme-linked  immunosorbent
assay (ELISA) according to the respective manufacturers’
protocols. To measure the level of angiopoietin-2, 30 μl of
undiluted aqueous humor of controls or patients with AMD
(18 cases for control and 13 cases for patients with AMD)
were prediluted with 70 μl of standard diluent buffer supplied
with  the  Human  Angiopoietin-2  ELISA  kit  (Invitrogen,
Camarillo, CA). One hundred μl of prediluted samples were
added to each well filled with 25 μl of incubation buffer and
then incubated with 50 μl of biotinylated anti-Ang-2 solution
at RT for 2 h. After the wells were aspirated and washed four
times, 100 μl of streptavidin-HRP working solution was added
to each well and incubated at RT for 30 min. Then the wells
were  washed  four  times  and  incubated  with  100  μl  of
stabilized  chromogen  at  RT  for  30  min  in  the  dark.  The
reaction was stopped with 100 μl of stop solution, and then
the absorbance was read at 450 nm. To assay the level of
IGFBP-7, the Human IGF-BP7 “SUPER X” ELISA kit was
purchased  from  Antigenix  America  (Huntington,  NY).  In
brief, 5 μl of each undiluted aqueous humor sample (30 cases
for control and 23 cases for patients with AMD) was diluted
with 95 μl of PBS containing 0.05% Tween-20 and 0.1% BSA,
loaded into each precoated well, and incubated at RT for 2 h.
After the wells were aspirated and washed four times, 100 μl
of 0.1 μg/ml of biotin-labeled tracer antibody was added and
incubated at RT for 1 h. After the solution was decanted, each
well  was  washed  four  times,  100  μl  of  streptavidin-HRP
conjugate (1:2,000 in diluent) was added, and the well was
incubated at RT for 30 min. TMB substrate solutions A and
B were mixed (1:1) just before being added and loaded into
each well, which was washed four times and then incubated
at RT for 10 min. Color development was stopped by adding
100 μl of stop solution, and the absorbance was read at 450
nm.
The TCCR level was measured with western blot. Briefly,
15 μl of undiluted aqueous humor of controls or patients with
AMD was heated in sodium dodecyl sulfate (SDS) sample
buffer (Laemmli) for 5 min at 94 °C, and subjected to SDS–
PAGE based on the Tris-Aspartate buffer system and then
transferred to nitrocellulose membrane. To minimize non-
specific binding, the membrane was blocked for 1 h at RT with
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2355% (w/v) skimmed milk in TBS-T buffer (25 mM Tris-HCl,
150  mM  NaCl  [pH  7.5],  and  0.05%  Tween-20)  and  then
incubated overnight at 4 °C with primary antibody to TCCR
(1:200;  R&D  Systems;  Minneapolis,  MN)  in  TBS-T
containing  5%  skimmed  milk.  Then  the  membrane  was
washed in TBS-T and probed for 1 h at RT with horseradish
peroxidase-conjugated antigoat secondary antibody (1:5,000;
Vector Laboratories; Burlingame, CA) in TBS-T containing
5%  skimmed  milk.  After  being  washed  in  TBS-T,  the
immunoreactive bands were visualized with ECL detection
reagent (Pierce; Rockford, IL).
To assay the expression levels and phosphorylation status
of p44/42 MAPK and β-actin, HUVECs were cultured in 12-
well plates coated with 1% gelatin and then treated with 100
pM recombinant human TCCR/WSX-1/Fc chimera protein or
human immunoglobulin G (IgG) Fc protein for 2, 5, or 30 min.
After 100 μl of SDS sample buffer was added, the samples
were  subjected  to  western  blot  using  antiphospho-p44/42
MAPK  (p-ERK,  1:1,000;  Cell  Signaling  Technology;
Danvers, MA), p44/42 MAPK (ERK, 1:2,000; Cell signaling),
or β-actin (1:1,000; Santa Cruz Biotechnology; Santa Cruz,
CA) antibodies.
Cell culture: HUVECs were obtained from ATCC (Manassas,
VA) and grown (37 °C, 5% CO2) in M199 (Thermo Fisher
Scientific;  Waltham,  MA)  with  20%  fetal  bovine  serum
(Thermo  Fisher  Scientific)  and  3  ng/ml  basic  fibroblast
growth factor (bFGF; Sigma-Aldrich; St. Louis, MO). The
cells were studied between passages 4 and 7.
Tube formation assay: Tube formation was performed by
placing  ice-cold  growth  factor-reduced  Matrigel  matrix
(8.2  mg/ml;  BD  Biosciences;  Franklin  Lakes,  NJ)  in  a
prechilled 96-well plate (50 μl/well) and incubating it at 37 °C
for 30 min to allow polymerization. Thereafter, HUVECs
(1×104 cells/well) were seeded on a Matrigel-coated 96-well
plate and incubated in the M199 media for 8 h in the presence
or  absence  of  20%  fetal  bovine  serum,  different
concentrations (10, 100, 1,000 pM) of recombinant human
TCCR/WSX-1/Fc chimera protein (R&D Systems), or human
IgG Fc protein (R&D Systems). Tube-like structures were
observed after 8 h and photographed under phase contrast
microscopy using an inverted Olympus microscope (Tokyo,
Japan) at 50× magnification. Quantification of the images was
performed in a blinded manner by counting total tubes per five
fields. The experiment was performed three times in triplicate
wells.
RESULTS
Analysis of secretory proteins in aqueous humor: To identify
novel secretory proteins for which the number changed in
patients with AMD, we analyzed aqueous humor by using a
membrane-based human antibody array kit. For convenience,
all 30 samples were mixed and subjected to antibody-array
analysis.  Using  an  array  designed  to  detect  507  proteins
(Figure 1A), we found that the number of several proteins
were changed in the aqueous humor of patients with AMD
compared to the control (Figure 1B). Angiopoietin-2 (Ang-2),
C-C  motif  chemokine  receptor  7  (CCR7),  CCR8,  CCR9,
ciliary neurotrophic factor (CNTF), C-X-C motif chemokine
ligand  14  (CXCL14/BRAK),  C-X-C  motif  chemokine
receptor 1 (CXCR1/IL-8 RA), CXCR2 (IL-8 RB), EGF-TM7
latrophilin-related protein (ETL), insulin-like growth factor
binding protein-related protein 1 (IGFBP-rp1/IGFBP-7), and
insulysin (insulin-degrading enzyme/IDE) were decreased in
the aqueous humor of patients with AMD. On the other hand,
the number of TCCR/WSX-1, transmembrane protein with
EGF-like  and  two  follistatin-like  domains  1  (TMEFF1/
Tomoregulin-1),  and  u-plasminogen  activator  (uPA)  were
increased in patients with AMD (Figure 1C).
Protein quantification: To verify each sample, we next used
quantitative analysis. Among the candidate proteins shown in
Figure 1B, Ang-2, IGFBP-7, and uPA are available for ELISA
analysis. As shown in Figure 2A, Ang-2 was decreased by
about 20% in patients with AMD compared with the control
group (p=0.074). IGFBP-7, however, did not appear to be
different between the groups (Figure 2B), and the level of uPA
was not in the detectable range (data not shown).
We also verified the number of proteins by using western
blot. Twenty-one samples in the control and AMD patient
groups were used for western blot using a specific antibody
against TCCR (Figure 3A). Densitometry data showed that
TCCR was increased significantly in the aqueous humor of
patients with AMD compared to the control group (p=0.0013)
(Figure 3B).
TCCR  promotes  angiogenesis  of  human  umbilical  vein
endothelial cells in vitro: To test whether TCCR could induce
angiogenesis  in  endothelial  cells,  tube  formation  was
measured using HUVECs in vitro. We found that exogenous
human  TCCR/WSX-1/Fc  chimera  protein  promoted  tube
formation in HUVECs (Figure 4A,B). However, the control
IgG did not show a similar outcome. ERK activation has been
known  to  be  closely  associated  with  tube  formation  of
HUVECs. As shown in Figure 4C, phosphorylation of ERK
was  increased  transiently  after  treatment  with  the  TCCR
protein. Taken together, these data show that TCCR activates
ERK and stimulates tube formation in endothelial cells.
DISCUSSION
In the present study, TCCR was significantly increased in the
aqueous humor of patients with AMD. Moreover, treatment
of endothelial cells with the extracellular domain of TCCR
induced angiogenesis. There are two possible pathways by
which TCCR could induce angiogenesis: First, TCCR acts as
a neutralizer of IL-27 and thus inhibits the antiangiogenic
effect of IL-27. IL-27 is known to bind the TCCR/gp130
receptor complex, activate the janus kinase/signal transducer
and  activator  of  transcription  (JAK/STAT)  pathway,  and
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236Figure 1. Expression levels of 507 proteins in aqueous humor of control or patients with age-related macular degeneration (AMD). A: The
list of human antibodies. B: The mixed aqueous humor samples were assayed directly with the RayBio® Biotin Label-based Human Antibody
Array kit. C: The following proteins were changed in the aqueous humor of patients with AMD compared to control: Ang-2, CCR7, CCR8,
CCR9, CNTF, CXCL14, CXCR1, CXCR2, ETL, IGFBP-7, and Insulysin (down-regulated); TCCR, TMEFF1, and uPA (upregulated).
Negative control (15) and positive control (16) represent internal controls.
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237induce the expression of antiangiogenic molecules, CXCL9
and CXCL10. However, in the absence of gp130, IL-27 just
binds  to  TCCR  and  cannot  transduce  its  antigangiogenic
signal to downstream. Second, soluble TCCR itself may act
as a trigger for angiogenesis in this process.
TCCR (also known as WSX-1 and IL-27 Rα) is a 96-kDa
type I cytokine receptor that functions as the ligand-binding
component of the receptor for IL-27 and functions with the
glycoprotein  130  (gp130)  coreceptor  to  induce  signal
transduction in response to IL-27. Upon binding of IL-27 to
its  receptor  complex  TCCR/gp130,  JAK1,  STAT1,  and
STAT3 are activated [11,12]. Several years ago, Feng et al.
[13] performed microarray experiments in primary human
endothelial cells by treatment with IL-27. The study showed
that IL-27 can induce the expression of CXCL9 and CXCL10
by 10- and nearly 60-fold in HUVECs. Both molecules are
known to inhibit tumor growth and metastasis due to their
antiangiogenic effects [14,15]. Therefore, the previous study
clearly  indicates  that  IL-27  acts  as  an  inhibitor  of
angiogenesis. This may be of clinical importance, since in
normal tissues only a small percentage of vascular endothelial
cells are positive for CXCR3, which is a receptor for IL-27-
induced CXCL10 [16]. The antiangiogenic effect of IL-27 is
derived  from  macrophages  and  dendritic  cells.  The  M1
Figure  2.  Enzyme-linked
immunosorbent assay (ELISA) data of
Ang-2 and IGFBP-7. The protein levels
of  Ang-2  (A)  and  IGFBP-7  (B)  in
aqueous humor samples were measured
using the ELISA kit (* p=0.074).
Figure  3.  Western  blot  of  T-cell
cytokine receptor (TCCR). A: Twenty-
one  aqueous  humor  samples  of  the
control  and  the  age-related  macular
degeneration  (AMD)  patient  groups
were assessed with western blot using a
specific antibody against TCCR. Upper
numbers  indicate  the  value  by
densitometry. B: The western blot data
were  quantified  with  a  densitometer
(**  p=0.0013).  The  y-axis  represents
arbitrary scanning units.
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238phenotype of macrophages has antiangiogenic properties by
producing  IL-12  and  interferon  alpha  (IFN-α)-related
chemokines  CXCL9,  CXCL10,  and  CXCL11  [17,18].  In
addition  to  macrophages,  recent  reports  have  shown  that
dendritic cells have direct and indirect effects on angiogenesis
[19,20]. Certain chemokines, such as chemokine (C-C motif)
ligand 2 (CCL2) and chemokine (C-X3-C motif) ligand 1
(CX3CL1), appear to be crucial for the accumulation of the
subretinal microglia and macrophages observed in AMD and
to participate in the development of retinal degeneration as
well as in choroidal neovascularization [21]. This relates to
the accumulation of macrophages in the subretinal space by
CCL2 and CX3CL1. The prolonged presence of macrophages
in  the  subretinal  space  is  associated  with  photoreceptor
degeneration [22,23] and the development of CNV in animal
models [24,25], which have been reported to involve possible
induction of angiogenesis. Taken together, increased TCCR
in patients with AMD may reduce the expression of CXCL9
and CXCL10 by neutralizing the effect of IL-27 with the
outcome being an angiogenic effect.
We also suggest the possibility that soluble TCCR may
serve as a ligand for angiogenesis. Several receptors have dual
roles for ligands as well as for the receptor itself. For example,
ephrins can activate forward signaling to Eph receptors and
reverse signaling through their cytoplasmic domain [26]. In
our study, we found that TCCR existed in the aqueous humor
is  elevated  in  patients  with  AMD  and  the  exogenous
extracellular  domain  of  TCCR  itself  activates  a  signaling
pathway  and  induces  angiogenesis  of  endothelial  cells.
Although we could not determine whether the level of the
whole TCCR protein changed and how TCCR was processed
to its cleaved form in patients with AMD, our study suggests
a novel function of TCCR in addition to its receptor function
against IL-27.
Although the precise mechanism of action of TCCR in
angiogenesis must be investigated more, inhibition of TCCR
signaling may be a possible strategy for application in patients
with AMD. Some examples are the neutralizing antibodies
against soluble TCCR, the small molecules inhibiting TCCR
cleavage,  and  the  chemicals  blocking  the  downstream
signaling induced by soluble TCCR-receptor coupling. If the
molecules with these inhibitory properties could be found and
are available, combinatorial therapeutic application of these
molecules with established antiangiogenic agents might be
useful in AMD therapy.
To conclude, we propose that the soluble form of TCCR/
WSX-1  induces  angiogenesis  in  the  aqueous  humor  and
therefore may be a potential therapeutic target in AMD.
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